MTHFR may be one of the most discussed—and misunderstood—genes in consumer health. A result can sound alarming when it is described as a “mutation,” yet the two results most people encounter are common polymorphisms found in large portions of the population.
Having an MTHFR variant is not the same as having a disease. For most people, it is a modest biological difference whose effect depends on folate status, vitamin B12, diet, medications, kidney function, age, pregnancy, and the rest of the genome.
What is MTHFR?
MTHFR is the gene that provides instructions for making methylenetetrahydrofolate reductase. The enzyme converts 5,10-methylene-THF to 5-methyl-THF (5-MTHF), the circulating form of folate used to help convert homocysteine to methionine. Methionine can then contribute to SAMe production and methylation reactions involved in gene regulation, cell maintenance, and neurotransmitter biology.
This pathway also relies on vitamin B12 and enzymes encoded by genes such as MTR, MTRR, SHMT1, BHMT, and CBS. That network is why a single MTHFR result cannot summarize “methylation” or predict health on its own.8
MTHFR helps the body use folate within a larger metabolic pathway. Common variants may change enzyme efficiency; they do not switch the pathway off.
C677T and A1298C: the two common variants
The best-studied variants are C677T (also written c.665C>T or rs1801133) and A1298C (c.1286A>C or rs1801131). Each person inherits one copy of the gene from each parent. “Heterozygous” means one copy carries the variant; “homozygous” means both do.
In the landmark laboratory study by Frosst and colleagues, the C677T CT genotype had approximately 65% of the measured MTHFR activity of the CC genotype, while TT had approximately 30%. These often-quoted estimates describe enzyme activity under study conditions—not a percentage of a person's overall methylation or health.4 A1298C was also associated with decreased enzyme activity, but its effects are generally more qualitative and context dependent, especially when considered alone.5
| Result | Common description | Typical interpretation |
|---|---|---|
| 677 CC | No C677T copies | Reference genotype; does not rule out folate or homocysteine issues. |
| 677 CT | One C677T copy | About 65% activity in the Frosst laboratory estimate; usually without clinical consequence. |
| 677 TT | Two C677T copies | About 30% activity in that estimate; homocysteine effects are most apparent when folate is low. |
| 1298 AC / CC | One or two A1298C copies | Usually has a smaller biochemical effect than 677TT and is not consistently linked to elevated homocysteine. |
| 677 CT + 1298 AC | Compound heterozygous | One copy of each variant; interpretation still depends on biomarkers and clinical context. |
Laboratory estimates of enzyme activity do not translate directly into a percentage of health, fertility, detoxification, or methylation capacity. Rare biallelic pathogenic variants that cause severe MTHFR deficiency are medically important but are not the same as these common polymorphisms.
How common are MTHFR variants?
C677T and A1298C are common worldwide, with frequencies that vary substantially by ancestry and geography. The CDC notes that, in the United States, more people have one or two C677T copies than have neither. That prevalence is one reason a positive result, by itself, is not evidence of illness.1,9
| Population context | General pattern | Important caveat |
|---|---|---|
| United States overall | More people have one or two 677T copies than have neither, according to the CDC. | National patterns combine diverse ancestry groups. |
| Mexican / Central American ancestry | 677T and 677TT are comparatively more frequent. | Frequency does not equal disease risk. |
| European ancestry | Intermediate 677T frequency, with meaningful regional variation. | Folate fortification changes biochemical effects. |
| African ancestry | 677T is generally less frequent; A1298C still occurs. | Broad labels do not predict an individual genotype. |
What does the evidence actually show?
Research spans biochemistry, observational studies, and clinical outcomes. These are not interchangeable. A variant may affect a biomarker without causing disease, and an association does not prove that changing the biomarker will change an outcome.
Homocysteine
The clearest effect is biochemical: 677TT can be associated with higher homocysteine, particularly when folate intake or status is low. In a meta-analysis of folic-acid intervention studies, the baseline difference between TT and CC was approximately 2.7–2.8 μmol/L and was substantially reduced after folic acid supplementation.7 Homocysteine can also rise because of vitamin B12 or B6 deficiency, kidney disease, hypothyroidism, smoking, age, and certain medications.
Blood folate follows the same context-dependent pattern. The CDC reports that people with 677TT average red-blood-cell folate levels about 16% lower than people with 677CC at the same folic acid intake—and emphasizes that folic acid intake matters more than genotype for blood folate concentration.1,6
Neural tube defects
Low folate around conception increases neural tube defect risk. Maternal or fetal C677T may modestly modify risk, but it does not replace the proven prevention strategy. The CDC recommends 400 micrograms of folic acid daily for everyone capable of becoming pregnant, including people with MTHFR variants. Those with a prior affected pregnancy or other high-risk circumstances need individualized medical guidance.1,10
Cardiovascular disease
Older studies reported modest associations between 677TT, homocysteine, and coronary disease, especially in low-folate settings. Meta-analysis of the total evidence made the causal picture less convincing. MTHFR genotype should not displace established risk assessment such as blood pressure, ApoB or LDL cholesterol, diabetes, smoking, family history, and coronary imaging when appropriate.11
Blood clots
Common MTHFR variants are not considered inherited thrombophilias. Major professional guidance advises against ordering MTHFR genotyping as part of a routine clotting evaluation. A clot history warrants evidence-based assessment, which may include factors such as antiphospholipid syndrome, factor V Leiden, prothrombin G20210A, surgery, immobility, estrogen exposure, cancer, and family history—not an assumption based on MTHFR.2,3,12
Pregnancy and miscarriage
Studies of MTHFR and recurrent pregnancy loss have produced inconsistent results and are vulnerable to differences in folate intake, ancestry, study design, and publication bias. Routine MTHFR testing is not recommended to explain infertility or miscarriage. Pregnancy loss deserves compassionate, clinically appropriate evaluation rather than a single-gene explanation.2,3
Mental health
L-methylfolate has been studied as adjunctive therapy in selected patients with SSRI-resistant depression, including research stratified by biomarkers and genotype. These trials do not establish that common MTHFR variants cause depression or that everyone with a variant benefits from methylfolate. Treatment decisions belong with a qualified clinician and are not determined by MTHFR status alone.13,14
Autism
Some case-control studies and meta-analyses report associations between common folate-pathway variants and autism spectrum disorder. The evidence is heterogeneous and does not support using MTHFR to diagnose autism, explain an individual’s autism, or prescribe unproven “detox” protocols. Autism is genetically and biologically complex.15
“Genotype tells you what may happen. Biomarkers tell you what is happening.”
A useful distinction for interpreting common variants
The MTHFR testing debate
Direct-to-consumer reports have made MTHFR results easy to find. Clinical usefulness is a different question. The American College of Medical Genetics and Genomics concluded that evidence does not support routine MTHFR polymorphism testing for thrombophilia evaluation, and its 2020 addendum maintained that guidance. Routine testing is also discouraged as an explanation for recurrent pregnancy loss or nonspecific symptoms.2,3
Testing may still appear within a broader genomic dataset or a specialist workup. When it does, the goal should be proportionate interpretation: confirm what was tested, distinguish a common polymorphism from a rare pathogenic variant, review relevant biomarkers, and avoid unsupported claims.
Folic acid, methylfolate, and folinic acid
“Natural” or “methylated” does not automatically mean safer or more effective. The right form depends on the purpose. Food folate supports nutrition; folic acid has the strongest evidence for neural tube defect prevention; prescription L-methylfolate has specific clinical uses; and folinic acid is used in particular medical contexts.
| Form | Where it is found / used | What to know |
|---|---|---|
| Food folate | Leafy greens, beans, citrus, avocado, liver | Part of a balanced diet; amounts and bioavailability vary. |
| Folic acid | Fortified foods and many supplements | Stable, well studied, and the only form proven to prevent neural tube defects. People with common MTHFR variants can process it.1 |
| 5-MTHF / L-methylfolate | Some supplements; prescription products | Already reduced and methylated. Not automatically required because of an MTHFR result; high doses can obscure B12 deficiency or cause adverse effects. |
| Folinic acid | Leucovorin; selected medical and medication-rescue uses | Not the same as folic acid or methylfolate. Use for a defined clinical indication. |
Before taking high-dose folate, consider vitamin B12 status and speak with a clinician—especially during pregnancy, when taking anticonvulsants or methotrexate, or when managing cancer treatment. Supplements can interact with care and more is not necessarily better.
How to understand your genetic test result
- Check the exact variant and genotype.“MTHFR positive” is incomplete. Look for rs1801133/C677T, rs1801131/A1298C, and whether one or two copies were reported.
- Check the test quality.Consumer raw data may contain errors. A medically consequential result may require confirmation in a clinical laboratory.
- Clarify the clinical question.Pregnancy planning, anemia, an elevated homocysteine result, a clot, and general curiosity require different evaluations.
- Look at relevant biomarkers.Depending on context: folate, vitamin B12, methylmalonic acid, homocysteine, complete blood count, kidney function, and established cardiovascular measures.
- Act on evidence, not fear.Support folate intake, avoid smoking, address proven risk factors, and discuss medication or supplement changes with a qualified clinician.
Genotype tells you what may happen. Biomarkers tell you what is happening. Clinical history tells you why it matters.
Whole genome sequencing: the bigger picture
A single-variant test answers a narrow question. Whole genome sequencing can examine MTHFR alongside genes such as MTR, MTRR, DHFR, FOLR1, and SLC19A1, as well as thousands of genes across health-related pathways. It can also preserve a broad dataset that may be reinterpreted as evidence evolves.
Depending on the laboratory, consent, and analysis, intended outputs may include common and rare variants, findings in medically actionable genes, carrier status, pharmacogenomic results, and selected polygenic risk estimates. Each category has different evidence standards and limitations; not every finding is clinically meaningful or actionable.
That breadth requires restraint. Most variants are benign or uncertain; associations may not transfer equally across ancestry groups; and a genomic result is not a diagnosis. Clinically significant findings may need confirmation, genetic counseling, and integration with family history, physical findings, imaging, and laboratory data.
The most useful model is whole genome and whole person: genome → pathway → biomarkers → phenotype → appropriate intervention → longitudinal measurement. Genetics can sharpen a question. It should not reduce a person to one result.
Frequently asked questions
What is MTHFR?
MTHFR is a gene that provides instructions for an enzyme involved in folate metabolism and the conversion of homocysteine to methionine. C677T and A1298C are common versions of this gene, not diagnoses.
Is an MTHFR variant dangerous?
Common C677T and A1298C variants are not diseases and are not usually dangerous by themselves. Their biochemical effects depend on folate status and wider health context. Rare pathogenic variants that cause severe MTHFR deficiency are different.
How common are MTHFR variants?
They are very common and their frequency varies by ancestry and geography. The CDC notes that in the United States, more people have one or two C677T copies than have neither.
Should I get tested for MTHFR?
Routine MTHFR testing is generally not recommended for blood clots, recurrent pregnancy loss, or nonspecific symptoms. If a result appears in broader genomic testing, interpret it with biomarkers and clinical history.
What does heterozygous MTHFR mean?
Heterozygous means one of your two MTHFR gene copies carries the reported variant. Homozygous means both copies do. Neither term, by itself, describes a disease or predicts symptoms.
How is an MTHFR variant treated?
A common variant does not need treatment simply because it is present. Care should address the person and any measured issue—such as low folate, vitamin B12 deficiency, or elevated homocysteine—with a clinician. Methylfolate is not automatically required.
References
- CDC. “MTHFR Gene Variant and Folic Acid Facts.” Updated July 16, 2026.
- Hickey SE, Curry CJ, Toriello HV. “ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing.” Genetics in Medicine. 2013;15(2):153-156. doi:10.1038/gim.2012.165.
- Bashford MT, Hickey SE, Curry CJ, Toriello HV; ACMG Professional Practice and Guidelines Committee. “Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing.” Genetics in Medicine. 2020;22(12):2125. doi:10.1038/s41436-020-0843-0.
- Frosst P, Blom HJ, Milos R, et al. “A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.” Nature Genetics. 1995;10(1):111-113. doi:10.1038/ng0595-111.
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. “A second genetic polymorphism in methylenetetrahydrofolate reductase associated with decreased enzyme activity.” Molecular Genetics and Metabolism. 1998;64(3):169-172. doi:10.1006/mgme.1998.2714.
- Tsang BL, Devine OJ, Cordero AM, et al. “Assessing the association between the MTHFR 677C>T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies.” American Journal of Clinical Nutrition. 2015;101(6):1286-1294. doi:10.3945/ajcn.114.099994.
- Colson NJ, Naug HL, Nikbakht E, Zhang P, McCormack J. “The impact of MTHFR 677 C/T genotypes on folate status markers: a meta-analysis of folic acid intervention studies.” European Journal of Nutrition. 2017;56(1):247-260. doi:10.1007/s00394-015-1076-x.
- Crider KS, Yang TP, Berry RJ, Bailey LB. “Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role.” Advances in Nutrition. 2012;3(1):21-38.
- Wilcken B, Bamforth F, Li Z, et al. “Geographical and ethnic variation of the 677C>T allele of 5,10-methylenetetrahydrofolate reductase: findings from over 7000 newborns from 16 areas worldwide.” Journal of Medical Genetics. 2003;40(8):619-625. doi:10.1136/jmg.40.8.619.
- Zhang T, Lou J, Zhong R, et al. “Genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature.” PLoS ONE. 2013;8(4):e59570. doi:10.1371/journal.pone.0059570.
- Lewis SJ, Ebrahim S, Davey Smith G. “Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?” BMJ. 2005;331:1053. doi:10.1136/bmj.38611.658947.55.
- Ray JG, Shmorgun D, Chan WS. “Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies.” Pathophysiology of Haemostasis and Thrombosis. 2002;32(2):51-58. doi:10.1159/000065076.
- Papakostas GI, Shelton RC, Zajecka JM, et al. “L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.” American Journal of Psychiatry. 2012;169(12):1267-1274. doi:10.1176/appi.ajp.2012.11071114.
- Papakostas GI, Shelton RC, Zajecka JM, et al. “Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients stratified by biomarker levels and genotype.” Journal of Clinical Psychiatry. 2014. doi:10.4088/JCP.13m08947.
- Li Y, et al. “Association between MTHFR C677T/A1298C and susceptibility to autism spectrum disorders: a meta-analysis.” BMC Pediatrics. 2020.